Press "Enter" to skip to content

Anal Fissure Treatment Market To Expand Market Worth To USD 2.6 Billion By 2023

Market Overview:

The intensification in the number of cases related to gastroenterology has increased the incidence of anal fissures thus increasing the market scope. Market reports connected with the healthcareindustry have been made available by Market Research Future who puts out reports on other sectors that have been currently published along with a report on this industry. The market is projected to earn revenue worth USD 2.6 billion while expanding at a CAGR of 5.2 % in the forecast period.

Get a Free Sample @

Issues relating to constipation and diarrhea are on the rise currently due to unhealthy diet patterns and proper bathroom hygiene practices. The prevalence of these mentioned factors is increasing the opportunities that can be utilized in connection with this sector. The market is also expected to be substantially influencedin the forecast period by the level of research and development being initiated by market contenders.

Competitive Analysis

The gaps in the market are filled due to the execution of proper supply chain strategies.The important success factors and players’ predilections are consistently growing by the strategies being used by market contenders.The enhancement in the products and services is the chief factor escalating the market’s productivity and controlling the trends that are acquiring distinction in the market.Besides, the introduction of new products and services will add additional impetus to the market progress. The development of the market is based on the drivers that are radically altering the market backdrop. The growth patterns are modified in tandem to the customer preferences to achieve maximum growth, and in the long run, profitability.The situation for growth plans has stimulated the market for potential new entrants.

renowned competitors profiled in the report are Healthy Life Pharma Private Limited, SRS Pharmaceuticals Pvt. ltd., Troikaa Pharmaceuticals Ltd., Geri-Care Pharmaceuticals, Novasep, Takeda Pharmaceutical Company Limited, Taj Pharmaceuticals Ltd., PurduePharma L.P

Segmental Analysis

  • The marke tfor anal fissure treatment is divided on the basis of drugs and surgery.
  • On the basis ofdrugs, the market has been segmentedinto stool softeners, calcium channel blockers, topical nitroglycerin, and others.
  • On the basis ofsurgery, the market has been segmentedinto anal dilation, lateral internal sphincterotomy,and others.

Detailed Regional Analysis

The regional analysis of the market perceives that the US is responsible for the majority market share owing to the encouraging reimbursement scenario and elevated expenditure on healthcare in the region. The rapid growth of new technology in the US is a significant factor prompting the considerable development of the market. The European region is the next major market owing to the huge level of incomes and rising awareness. The Asia Pacific region is a rapidly growing region in the market due to the largely unmet needs which are led especially by India and China. The Middle East & Africa market is governed by the Gulf nations chiefly Saudi Arabia and UAE. The backward regions of Africa are expected to be a slow-growing region due to poverty, volatile political conditions and limited healthcare penetration.

Access Full Report Details @


Industry Updates:

Jan 2018Researchers have finalized patient enrollment in a phase 3 trial for RDD-1219 for treatment of chronic anal fissures. A randomized, double-blind study in Europe will examine the efficacy and safety of two dosing regimens against a placebo.